Daiichi Sankyo launches global R&D restructuring, looking to slash costs in an overhaul
You can add Japan’s Daiichi Sankyo to the list of pharma companies restructuring their R&D organizations.
Like Takeda before it and a whole lineup of US and European pharmas, Daiichi Sankyo is shuttering a research facility in India and axing 170 staffers. And the company says it is in the process of slashing costs around the world as it frees up cash.
In a statement, the company noted:
Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.